AI Article Synopsis
- Vascular calcification (VC) is common in chronic kidney disease (CKD) patients, primarily caused by high phosphate levels.
- Intravenous iron sucrose (IS) is often used for treating anemia in CKD patients, but its role in relation to VC is still debated.
- This study shows that IS can help reduce VC at lower doses but may cause iron overload at higher concentrations, suggesting its potential benefits and risks in hyperphosphatemic patients.
Article Abstract
The high incidence of vascular calcification (VC) in patients with chronic kidney disease (CKD) has become an important clinical subject. Hyperphosphatemia is a primary cause of CKD-related VC. Intravenous iron sucrose (IS) is commonly used to treat anemia in CKD patients, and is effective and well tolerated worldwide. However, the interaction between iron and VC remains controversial, and the underlying mechanisms are yet to be clarified. In the present study, ex vivo normal rat aortic rings were cultured with various concentrations of phosphate and IS, and the levels of calcium and iron depositions, oxidative injury, as well as phenotypic marker genes were detected. To the best of our knowledge, the present study is the first to report that IS is a double-edged sword in high phosphate media-induced VC which not only alleviates VC in a dose-dependent manner but also leads to iron overload in vasculature when in high concentration. IS is a promising agent for VC prevention in patients with hyperphosphatemia and iron deficiency. Meanwhile, the appropriate blood concentration of IS in patients with hyperphosphatemia needs to be explored clinically.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00223-020-00804-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!